Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
Brain : a Journal of Neurology|June 5, 2014
Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergeticsOscar G Vidaurre, Jeffery D Haines, Ilana Katz Sand, et al.
Nature Medicine|August 20, 2025
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Brain : a Journal of Neurology|July 11, 2019
Early complement genes are associated with visual system degeneration in multiple sclerosisKathryn C Fitzgerald, Kicheol Kim, Matthew D Smith, et al.
Lancet (London, England)|September 10, 2019
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Annals of Clinical and Translational Neurology|March 22, 2018
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS studyDavid H Miller, Fred D Lublin, Maria Pia Sormani, et al.
Annals of Neurology|August 19, 2007
Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick, Deborah Miller, Steve Hass, et al.
Annals of Clinical and Translational Neurology|May 8, 2024
Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosisKaarina Kowalec, Arvid Harder, Casandra Dolovich, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 27, 2021
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Jeffrey L Bennett, Ho Jin Kim, et al.
Annals of Neurology|August 7, 2025
Depression Polygenicity and Disease Activity and Disability Worsening in Multiple SclerosisAli Manouchehrinia, Kathryn C Fitzgerald, Amber Salter, et al.
Contemporary Clinical Trials|August 14, 2016
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosisRobert J Fox, Christopher S Coffey, Merit E Cudkowicz, et al.
Pageof 13